Methods for treating conditions associated with MASP-2 dependent complement activation
First Claim
1. A method of inhibiting MASP-2-dependent complement activation in a subject in need thereof, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
3 Assignments
0 Petitions
Accused Products
Abstract
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASp-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
Citations
58 Claims
- 1. A method of inhibiting MASP-2-dependent complement activation in a subject in need thereof, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 15. A method of inhibiting MASP-2-dependent complement activation in a subject in need thereof, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to selectively inhibit MASP-2-dependent complement activation without substantially inhibiting C1q-dependent complement activation.
-
24. A composition for inhibiting MASP-2-dependent complement activation comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
-
25. A method of manufacturing a medicament for use in inhibiting the effects of MASP-2-dependent complement activation in living subjects in need thereof, comprising combining a therapeutically effective amount of a MASP-2 inhibitory agent in a pharmaceutical carrier.
- 26. A method of treating a subject suffering from a MASP-2-dependent complement mediated vascular condition comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 28. A method of treating a subject suffering from a MASP-2-dependent complement mediated condition associated with an ischemia-reperfusion injury comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
30. A method of treating and/or preventing atherosclerosis in a subject in need thereof, comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 31. A method of treating a subject suffering from a MASP-2-dependent complement mediated condition associated with an inflammatory gastrointestinal disorder comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 33. A method of treating a subject suffering from a MASP-2-dependent complement mediated pulmonary condition comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 35. A method of inhibiting MASP-2-dependent complement activation in a subject that has undergone, is undergoing, or will undergo an extracorporeal reperfusion procedure comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 37. A method of treating a subject suffering from a MASP-2-dependent complement mediated musculoskeletal condition comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 39. A method of treating a subject suffering from a MASP-2-dependent complement mediated renal condition comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 41. A method of treating a subject suffering from a MASP-2-dependent complement mediated skin condition comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 43. A method of inhibiting MASP-2-dependent complement activation in a subject that has undergone, is undergoing, or will undergo an organ or tissue transplant procedure comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 45. A method of treating a subject suffering from a MASP-2-dependent complement mediated condition associated with a nervous system disorder or injury comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-dependent complement activation.
- 47. A method of treating a subject suffering from a MASP-2-dependent complement mediated condition associated with a blood disorder comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 49. A method of treating a subject suffering from a MASP-2-dependent complement mediated condition associated with a urogenital condition comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 51. A method of treating a subject suffering from a MASP-2-dependent complement mediated condition associated with nonobese diabetes (Type-1 diabetes or Insulin-dependent diabetes mellitus) and/or complications associated with Type-1 or Type-2 (adult onset) diabetes comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
53. A method of inhibiting MASP-2-dependent complement activation in a subject that has undergone, is undergoing, or will undergo chemotherapeutic treatment and/or radiation therapy comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
-
54. A method of treating a subject suffering from a malignancy comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 55. A method of treating a subject suffering from an endocrine disorder comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
- 57. A method of treating a subject suffering from a complement mediated ophthalmologic condition comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
Specification